|
1
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, et al: Randomized, multinational, phase III study of
docetaxel plus platinum combinations versus vinorelbine plus
cisplatin for advanced non-small-cell lung cancer: The TAX 326
study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cobo M, Isla D, Massuti B, Montes A,
Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G,
Muñoz MA, et al: Customizing cisplatin based on quantitative
excision repair cross-complementing 1 mRNA expression: A phase III
trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guha U, Chaerkady R, Marimuthu A,
Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE,
Minna JD, et al: Comparisons of tyrosine phosphorylated proteins in
cells expressing lung cancer-specific alleles of EGFR and KRAS.
Proc Natl Acad Sci USA. 105:14112–14117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taron M, Ichinose Y, Rosell R, Mok T,
Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, et al:
Activating mutations in the tyrosine kinase domain of the epidermal
growth factor receptor are associated with improved survival in
gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer
Res. 11:5878–5885. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Costa DB, Kobayashi S, Tenen DG and
Huberman MS: Pooled analysis of the prospective trials of gefitinib
monotherapy for EGFR-mutant non-small cell lung cancers. Lung
Cancer. 58:95–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marchetti A, Martella C, Felicioni L,
Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli
F, Mezzetti A, et al: EGFR mutations in non-small-cell lung cancer:
Analysis of a large series of cases and development of a rapid and
sensitive method for diagnostic screening with potential
implications on pharmacologic treatment. J Clin Oncol. 23:857–865.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lafarge S, Sylvain V, Ferrara M and Bignon
YJ: Inhibition of BRCA1 leads to increased chemoresistance to
microtubule-interfering agents, an effect that involves the JNK
pathway. Oncogene. 20:6597–6606. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Husain A, He G, Venkatraman ES and Spriggs
DR: BRCA1 up-regulation is associated with repair-mediated
resistance to cis-diamminedichloroplatinum(II). Cancer Res.
58:1120–1123. 1998.PubMed/NCBI
|
|
14
|
Bhattacharyya A, Ear US, Koller BH,
Weichselbaum RR and Bishop DK: The breast cancer susceptibility
gene BRCA1 is required for subnuclear assembly of Rad51 and
survival following treatment with the DNA cross-linking agent
cisplatin. J Biol Chem. 275:23899–23903. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abbott DW, Thompson ME, Robinson-Benion C,
Tomlinson G, Jensen RA and Holt JT: BRCA1 expression restores
radiation resistance in BRCA1-defective cancer cells through
enhancement of transcription-coupled DNA repair. J Biol Chem.
274:18808–18812. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mullan PB, Quinn JE, Gilmore PM,
McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P,
Song YH, et al: BRCA1 and GADD45 mediated G2/M cell cycle arrest in
response to antimicrotubule agents. Oncogene. 20:6123–6131. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Quinn JE, Kennedy RD, Mullan PB, Gilmore
PM, Carty M, Johnston PG and Harkin DP: BRCA1 functions as a
differential modulator of chemotherapy-induced apoptosis. Cancer
Res. 63:6221–6228. 2003.PubMed/NCBI
|
|
18
|
Chabalier C, Lamare C, Racca C, Privat M,
Valette A and Larminat F: BRCA1 downregulation leads to premature
inactivation of spindle checkpoint and confers paclitaxel
resistance. Cell Cycle. 5:1001–1007. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sobhian B, Shao G, Lilli DR, Culhane AC,
Moreau LA, Xia B, Livingston DM and Greenberg RA: RAP80 targets
BRCA1 to specific ubiquitin structures at DNA damage sites.
Science. 316:1198–1202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim H, Chen J and Yu X: Ubiquitin-binding
protein RAP80 mediates BRCA1-dependent DNA damage response.
Science. 316:1202–1205. 2007. View Article : Google Scholar : PubMed/NCBI
|
